Contact
Home • ISPOR Europe 2023

Dig Deeper, Go Further.

…with our Value, Pricing & Access experts.

Learn about Value, Pricing & AccessExplore all we do

Join us at ISPOR Europe.

We’re a proud sponsor and exhibitor at this November’s ISPOR Europe in Copenhagen, Denmark.
Hear from one of our experts.

 

Where to find us.

C2-011

Our booth

You can find our exhibition space at C2-011. Check out the ISPOR conference map.

20+

Featured posters

Engage with our colleagues at our featured posters for deeper dive into our work.

1

Sponsored educational symposium

Proud to partner with AstraZeneca and Daiichi-Sankyo on an educational symposium.

The poster titles you might want to visit.

Don’t miss out on the poster sessions throughout the duration of the conference for a chance to view some of our recent work across a range of topics.

Here are some of our titles

  1. How immunotherapies have altered the future of cancer treatment: Patients living longer, healthier lives.
  2. Carer burden: Is HTA helping or harming the gender health gap?
  3. Utilisation of RWE in HTA appraisals in England, Scotland, Germany and France.
  4. The use of qualitative methods in the NICE HST deliberative process.
  5. The impact of the disease severity modifier on NICE technology appraisal decisions.
  6. Natural language processing to support the abstract selection during systematic literature review.
  7. Comparisons of economic evaluation guidelines between Japan and six countries (England, France, Germany, Sweden, Canada, and Australia).
  8. Retrospective analysis of the French early access experience following the 2021 reform.
  9. EUnetHTA’s HTA Core Model®: A critical assessment and future outlook.
  10. Review of HTA evaluation for gene therapies and their future implications in Europe.
  11. Reimbursement of CAR-T cell therapies in Europe: Key challenges from precedents and lessons for future.
  12. Evolution of timeframes within the overall time-to-market since marketing authorisation for new innovative-presumed products in France since the first published economic opinion.
  13. CAR-T cell therapies pathway: Evolution of management and of costing methodology in the French cost-effectiveness analyses (CEA) landscape.
  14. Impact of the 2020 update of the French HAS guidelines for economic evaluation on the economic opinions issued by the Economic Evaluation and Public Health Committee (CEESP).
  15. Recent advances in voluntary European cross-border collaborations in joint HTA and drug pricing/procurement.
  16. The role of EUnetHTA 21 in promoting patients’ engagement.
  17. A comparison of the UK and Australian interim value sets for the Weight-Specific Adolescent Instrument for Economic Evaluation (WAItE).
  18. Evolution of French efficiency opinions published by the Economic Evaluation and Public Health Committee (CEESP) in oncology.
  19. Evolution of French economic opinions published by the Economic Evaluation and Public Health Committee (CEESP).
  20. Analysis of the impact of early access decisions on pricing and reimbursement decisions in France.
  21. Health technology assessment requirements: Sensitive to bacteriophage products or too resistant to change?

About the sponsored educational symposium.

Putnam is partnering with AstraZeneca and Daiichi-Sankyo, who are sponsoring an educational symposium: ‘Is there any hope for the Value of Hope?’

The expert panel will include:

  • Moderator, Louise Longworth, PhD, Putnam
  • Meindert Boysen, PharmD, NICE
  • Lou Garrison, PhD, University of Washington
  • James Ryan, MSc, AstraZeneca
  • and Bettina Ryll, MD, PhD, Melanoma Patient Network Europe

Join us in this informative session to learn more about The Value of Hope.

More details here.

Bridging Science & StrategyTM.

We are a leading scientific and strategic consulting partner that helps the global life science community make confident decisions, build value, and bring life-changing innovations to clinicians and patients. ​

Our Value, Pricing & Access Services.

Tap to view Value, Pricing & Access Strategy

Value, Pricing & Access Strategy

Learn more
Tap to view HEOR Evidence Generation

HEOR Evidence Generation

Learn more
Tap to view Evidence Synthesis & RWE Generation

Evidence Synthesis & RWE Generation

Learn more

Latest Insights.

Medicare price negotiation: Putnam’s round one picks

This paper outlines predictions regarding drugs likely to be impacted by Medicare Price Negotiation in 2026 and implications in subsequent years.

Read more

HTA evidence generation and preparedness for a novel oncology treatment

Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment.

Read more

Early value insights to drive value definition and evidence need to produce TrPP

The client wanted to understand the key drivers of value for the new treatment for sleep disorders including narcolepsy.

Read more

The Inflation Reduction Act: A tale of two drugs

Putnam is developing tools and insights to help manufacturers assess and realize opportunities and mitigate risks from Inflation Reduction Act.

Read more

Leaders attending.

Clement Francois

Partner, HTA and Market Access Operations

Read bio

Donna Fountain

Partner, Market Access

Read bio

Michael Lees

Partner, Market Access and Operations Lead

Read bio

Cormac Sammon

Partner, RWE & Data Analytics

Read bio

Catriona Crossan

Principal, Head of Health Economic Modelling, HEOR

Read bio

Jasmine Farrington

Read bio

Yemi Oluboyede

Principal, Health Economics and Outcomes Research

Read bio

Frauke Becker

Principal, Health Economics and Outcomes Research (HEOR)

Read bio

Marine Sivignon

Principal, HTA operations

Read bio

Sylvaine Barbier

Principal, RWE & Biostatistics

Read bio

Céline Quélen

Principal, RWE and Data Analytics

Read bio

Alex Turner

Principal, RWE & Data Analytics

Read bio

Patrycja Jaros

Director, Market Access

Read bio

Roelien Postema

Principal Market Access

Read bio

Cécile Rémuzat

Principal, Market Access Strategy

Read bio

Rachael Doran

Director, Market Access

Read bio

Aurelie Meunier

Director, HEOR

Read bio

Ravi Potluri

Partner, HEOR & RWE

Read bio

Eric Auger

Partner, VPA Practice Lead

Read bio

Joanne Evason

Partner

Read bio

Mateusz Nikodem

Director in RWE and Data Analytics

Read bio

Get in touch.

Looking to get in touch with an expert or team member? Tell us how we can help.

Contact us